AUG 04, 2022
FDA Approves Second Biosimilar in Ophthalmology
Coherus Biosciences announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar product to Lucentis (ranibizumab injection).